Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals Inc. (ARWR) received a Rule 144 notice from director Adeoye Olukotun regarding a proposed sale of common stock. The filing states an intention to sell 2,000 shares of Arrowhead common stock through Merrill Lynch, with an aggregate market value of $173,876.47, on or about 08/18/2026 on NASDAQ. The company reports 141,254,467 shares outstanding. The 2,000 shares to be sold were acquired from the issuer as compensation on 12/18/2025.

Key Figures

Shares to be sold: 2,000 shares Aggregate market value of shares to be sold: $173,876.47 Shares outstanding: 141,254,467 shares +2 more

5 metrics

Shares to be sold 2,000 shares Common stock proposed to be sold by Adeoye Olukotun under Rule 144

Aggregate market value of shares to be sold $173,876.47 Aggregate market value of the 2,000 common shares covered by the notice

Shares outstanding 141,254,467 shares Common shares outstanding for Arrowhead Pharmaceuticals in the Form 144

Approximate sale date 08/18/2026 Approximate date of sale for the 2,000 common shares on NASDAQ

Acquisition date of shares 12/18/2025 Date the 2,000 shares were acquired as compensation from the issuer

Key Terms

Rule 144, aggregate market value, securities to be sold

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

aggregate market value financial

"2000 | 173876.47 | 141254467 | 08/18/2026 | NASDAQ"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

securities to be sold financial

"144: Securities To Be Sold"

FAQ

What sale of Arrowhead Pharmaceuticals (ARWR) shares is disclosed in this Form 144?

The notice reports that director Adeoye Olukotun intends to sell 2,000 shares of Arrowhead Pharmaceuticals common stock under Rule 144. The proposed sale will be executed through Merrill Lynch on NASDAQ.

What is the aggregate market value of the ARWR shares to be sold by Adeoye Olukotun?

The filing lists an aggregate market value of $173,876.47 for the planned sale of 2,000 ARWR shares. This value reflects the market price at the time referenced in the notice.

How many Arrowhead Pharmaceuticals (ARWR) shares are outstanding according to this notice?

Arrowhead Pharmaceuticals reports 141,254,467 shares outstanding of common stock in connection with this Form 144 notice. This figure provides context for the size of the proposed 2,000-share sale.

When were the ARWR shares to be sold acquired by Adeoye Olukotun?

The 2,000 Arrowhead Pharmaceuticals shares were acquired on 12/18/2025 as compensation from the issuer. This acquisition date and nature are disclosed in the securities-to-be-sold section.

When is the planned sale date for the 2,000 ARWR shares under Rule 144?

The proposed sale date listed is on or about 08/18/2026. This date appears as the approximate date of sale for the 2,000 Arrowhead Pharmaceuticals common shares to be sold on NASDAQ.

Through which broker will the ARWR shares be sold according to the Form 144?

The filing identifies Merrill Lynch, located at 75 Rockefeller Plaza in New York, as the broker for the proposed sale of 2,000 ARWR common shares on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:34 PM Accepted by SEC EDGAR 08/18/2026 - 05:31 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001242615
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arrowhead Pharmaceuticals Inc.
SEC File Number	001-38042
Address of Issuer	177 E. Colorado Blvd Ste 700 Pasadena CALIFORNIA 91105
Phone	6266964702
Name of Person for Whose Account the Securities are To Be Sold	Adeoye Olukotun
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 75 Rockefeller Plz 2nd Flr New York NY 10019	2000	173876.47	141254467	08/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/18/2025	Compensation	Issuer			2000	12/18/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Adeoye Olukotun
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)